Exosomes Derived from BMSCs Treated with CeONPs Ameliorate Radiation-Induced Jaw Bone Injury via miR-21-5p/STAT3 Axis-Mediated Osteogenesis and ROS Scavenging
Zhang Z., Li H., Huang C., Mou T., Tian J., Ge Z.
Animal Study, published in Pharmaceutics (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Pharmaceutics (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41754958
- PMCID
- PMC12943933
- DOI
- 10.3390/pharmaceutics18020216
Abstract (original English)
Background/Objectives : Radiation-induced jaw bone injury is a severe and refractory complication following radiotherapy, and the key to treatment is promoting osteogenic differentiation and alleviating oxidative stress injury in irradiated BMSCs. Cerium oxide nanoparticles (CeONPs) exhibit considerable research potential in various oxidative stress injury-related diseases due to their excellent reactive oxygen species (ROS) scavenging capacity; however, its biosafety risk makes direct application in disease treatment a matter of controversy. Methods : Recent evidence suggests that treating cells with nanoparticles can regulate the content of exosomes, enhancing the regenerative potential of exosomes. Accordingly, this study was designed to explore the therapeutic effects and underlying mechanism of exosomes derived from BMSCs treated with CeONPs (BMSC-Ce-exos) in radiation-induced jaw bone injury. Results : In vitro, 25 μg/mL CeONPs were identified as the optimal treatment concentration; BMSC-Ce-exos significantly promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs. In vivo, BMSC-Ce-exos notably promoted bone formation and decreased the ROS levels in rats with radiation-induced jaw bone injury. miRNA sequencing revealed that BMSC-Ce-exos were highly enriched with miR-21-5p, which promoted the osteogenic differentiation and reduced the ROS lev
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.